keyword
MENU ▼
Read by QxMD icon Read
search

Chronic hepatitis c treatment

keyword
https://www.readbyqxmd.com/read/28942625/current-status-of-and-strategies-for-hepatitis-c-control-in-south-korea
#1
REVIEW
Beom Kyung Kim, Eun Sun Jang, Jeong Han Kim, Soo Young Park, Song Vogue Ahn, Hyung Joon Kim, Do Young Kim
Chronic hepatitis C (CHC) is caused by hepatitis C virus (HCV) infection. HCV infection causes acute hepatitis, and the majority of those infected progress to chronic hepatitis, and some of them develop cirrhosis and hepatocellular carcinoma. Transmission of HCV is parenteral, and the major transmission routes include drug abuse, insecure injections or medical procedures, contaminated syringes or needles, sexual contact with an HCV-infected person, vertical infection of newborns by infected mothers, the transfusion of blood or blood products contaminated with viruses, and organ transplants...
September 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28942620/current-status-and-strategies-for-viral-hepatitis-control-in-korea
#2
REVIEW
Dong Hyun Sinn, Eun Ju Cho, Ji Hoon Kim, Do Young Kim, Yoon Jun Kim, Moon Seok Choi
Viral hepatitis is one of major global health challenges with increasing disease burden worldwide. Hepatitis B virus and hepatitis C virus infections are major causes of chronic liver diseases. They can lead to cirrhosis, hepatocellular carcinoma, and death in significant portion of affected people. Transmission of hepatitis B virus can be blocked by vaccination. Progression of hepatitis B virus-related liver diseases can be prevented by long-term viral suppression with effective drugs. Although vaccine for hepatitis C virus is currently unavailable, hepatitis C virus infection can be eradicated by oral direct antiviral agents...
September 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28939957/effect-of-hepatitis-c-treatment-with-ombitasvir-paritaprevir-r%C3%A2-%C3%A2-dasabuvir-on-renal-cardiovascular-and-metabolic-extrahepatic-manifestations-a-post-hoc-analysis-of-phase-3-clinical-trials
#3
Darshan A Mehta, Eric Cohen, Mariem Charafeddine, Daniel E Cohen, Yanjun Bao, Yuri Sanchez Gonzalez, Tram T Tran
INTRODUCTION: We analyzed phase 3 trial data of ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) ± ribavirin (RBV) in genotype 1 chronic hepatitis C patients to investigate the impact of 3D ± RBV on renal, cardiovascular and metabolic extrahepatic manifestations (EHMs), including persistency 52 weeks post treatment and differential impact by EHM disease severity. METHODS: Estimated glomerular filtration rate (eGFR), fasting triglyceride and fasting glucose values from clinical trials were used to assess renal, cardiovascular and metabolic EHMs, respectively...
September 22, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28935432/effectiveness-of-ravidasvir-plus-sofosbuvir-in-interferon-na%C3%A3-ve-and-treated-patients-with-chronic-hepatitis-c-genotype-4
#4
Gamal Esmat, Tamer Elbaz, Maissa El Raziky, Asmaa Gomaa, Mahmoud Abouelkhair, Hadeel Gamal El Deen, Aliaa Sabry, Mohamed Ashour, Naglaa Allam, Mohamed Abdel-Hamid, Ola Nada, Sherine Helmy, Hanaa Abdel-Maguid, Richard Colonno, Nathaniel Brown, Eric Ruby, Pamela Vig, Imam Waked
Although treatment of hepatitis C (HCV) and HCV-genotype-4 (GT4) has become very effective, yet treatment is very expensive, and affordable options are needed especially in limited resource countries. OBJECTIVE: To assess the efficacy and safety of the combination of ravidasvir (an NS5A inhibitor) and sofosbuvir to treat chronic HCV-GT4 infected patients. DESIGN: A total of three hundred patients with HCV-GT4 infection were recruited in 3 groups: treatment-naïve patients with or without compensated Child-A cirrhosis (Group 1); interferon-experienced patients without cirrhosis (Group 2); and interferon-experienced patients with cirrhosis (Group 3)...
September 18, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28933704/the-association-between-serum-cytokine-and-chemokine-levels-and-antiviral-response-by-entecavir-treatment-in-chronic-hepatitis-b-patients
#5
Mio Kurihara, Masataka Tsuge, Eisuke Murakami, Nami Mori, Waka Ohishi, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Hiromi Abe-Chayama, Tomokazu Kawaoka, Daiki Miki, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yizhou Zhang, Grace Naswa Makokha, C Nelson Hayes, Kazuaki Chayama
BACKGROUND: Although Nucleos(t)ide analogue therapy is thought to suppress chronic hepatitis B(CHB) via regulation of inflammatory cytokines/chemokines, the mechanism is still unclear. In this study, serum cytokine/chemokine levels were measured in CHB patients treated with entecavir, and the association with antiviral response was analyzed. METHODS: Seventy-eight Japanese patients with CHB were enrolled, and serum cytokine/chemokine levels were measured at baseline and at 12, 24, and 48 weeks of entecavir treatment using the MULTIPLEX kit...
September 21, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28933180/-viral-hepatitis-c-and-organ-transplantation
#6
Libuše Husová, Vladimír Mejzlík
At the Centre for Cardiovascular and Transplantation Surgery, Brno (CKTCH), a total of 638 liver transplantations were performed from the beginning of the transplantation programme on 2/2 1983 to 1/1 2017. Of the overall number of 638 transplantations indicated based on cirrhosis with chronic hepatitis C (HCV), 68 patients (11 %) underwent liver transplantation. Patients with HCV diagnosis were treated both while on the waiting list and after liver transplantation (LT). There was interferon as well as interferon-free therapy used during the treatment...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28933169/-history-and-presence-of-hepatitis-b%C3%A2-and-c%C3%A2-therapy
#7
Petr Husa
Infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are the worlds major causes of chronic liver disease. Care of patients infected with HBV and HCV and/or over the last 20 years has significantly improved thanks to the better understanding of the pathophysiology of disease, improvement of diagnostic, therapeutic and preventive options. The goal of treatment of chronic hepatitis B is to extend the length of life and improve its quality through the barriers of the progression of chronic hepatitis to cirrhosis, decompensation cirrhosis and hepatocellular carcinoma (HCC)...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28930257/physicochemical-properties-antioxidant-and-cytotoxic-activities-of-crude-extracts-and-fractions-from-phyllanthus-amarus
#8
Van Tang Nguyen, Jennette A Sakoff, Christopher J Scarlett
Background:Phyllanthus amarus (P. amarus) has been used as a medicinal plant for the prevention and treatment of chronic ailments such as diabetes, hepatitis, and cancer. Methods: The physicochemical properties, antioxidant and cytotoxic activities of crude extracts and fractions from P. amarus were determined using spectrophotometric method. Results: The P. amarus methanol (PAM) extract had lower levels of residual moisture (7.40%) and water activity (0.24) and higher contents of saponins, phenolics, flavonoids, and proanthocyanidins (1657...
June 18, 2017: Medicines (Basel, Switzerland)
https://www.readbyqxmd.com/read/28929515/treatment-of-hepatitis-c-virus-infection-with-direct-acting-antiviral-drugs-is-safe-and-effective-in-patients-with-hemoglobinopathies
#9
Raffaella Origa, Maria Laura Ponti, Aldo Filosa, Alfonso Galeota Lanza, Antonio Piga, Giorgio Maria Saracco, Valeria Pinto, Antonino Picciotto, Paolo Rigano, Salvatore Madonia, Rosamaria Rosso, Domenico D'Ascola, Maria Domenica Cappellini, Roberta D'Ambrosio, Immacolata Tartaglione, Lucia De Franceschi, Barbara Gianesin, Vito Di Marco, Gian Luca Forni
Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few...
September 20, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28929412/glecaprevir-pibrentasvir-first-global-approval
#10
Yvette N Lamb
A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET™ (EU); MAVYRET™ (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1-6) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both...
September 19, 2017: Drugs
https://www.readbyqxmd.com/read/28928168/factors-that-support-successful-transition-to-the-community-among-women-leaving-prison-in-british-columbia-a-prospective-cohort-study-using-participatory-action-research
#11
Patricia A Janssen, Mo Korchinski, Sarah L Desmarais, Arianne Y K Albert, Lara-Lisa Condello, Marla Buchanan, Alison Granger-Brown, Vivian R Ramsden, Lynn Fels, Jane A Buxton, Carl Leggo, Ruth Elwood Martin
BACKGROUND: In Canada, the number of women sentenced to prison has almost doubled since 1995. In British Columbia, the rate of reincarceration is 70% within 2 years. Our aim was to identify factors associated with recidivism among women in British Columbia. METHODS: We prospectively followed women after discharge from provincial corrections centres in British Columbia. We defined recidivism as participation in criminal activity disclosed by participants during the year following release...
September 13, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28927676/a-pilot-study-to-expand-treatment-of-chronic-hepatitis-c-in-resource-limited-settings
#12
REVIEW
Poonam Mathur, Emily Comstock, Edward McSweegan, Natalia Mercer, Nongthombam Suraj Kumar, Shyamasundaran Kottilil
The past five years have seen a revolution in the treatment of chronic hepatitis C, as short duration oral regimens of direct-acting antiviral drugs (DAAs), with nearly 100% cure rates for all genotypes, have replaced longer courses of ribavirin and injected interferon. Although initially very expensive, these DAAs are now becoming available in generic equivalents in countries with large numbers of chronically infected people, such as India. However, a number of obstacles may hinder the delivery of these drugs in resource-limited settings, including lack of access to diagnostic testing and the restriction of treatment to a small number of medical specialists...
September 16, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28927498/drug-treatment-for-chronic-hepatitis-c-infection-and-cancer-risk
#13
Marcus-Alexander Wörns, Peter Robert Galle, Stefan Zeuzem, Peter Schirmacher, Michael Manns, Arndt Vogel
BACKGROUND: In patients with chronic hepatitis C infection, a sustained virologic response (SVR) to interferon-based therapy markedly decreases the incidence of hepatocellular carcinoma (HCC) over the long term. This is also true for patients who have hepatic cirrhosis, as well as for those with HCC-with or without cirrhosis-who have undergone resection or ablation with curative intent. Recent publications, however, have reported a higher incidence of HCC among patients in both of these subgroups who were treated with direct antiviral agents (DAA) rather than interferon-based therapy...
September 4, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28925824/can-we-go-for-a-shorter-treatment-course-in-chronic-hepatitis-c-more-inspiring-cases
#14
Rosa Zampino, Martina Vitrone, Antonio Parrella, Enrico Ragone, Emanuele Durante-Mangoni
Current interest in HCV therapy with direct acting antivirals is focused on shortening treatment length. We managed two cirrhotics who achieved virological cure after 4 weeks of ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin treatment. Analysis to identify potential predictive factors for a successful outcome with a shorter treatment course was conducted.
September 19, 2017: Journal of Chemotherapy
https://www.readbyqxmd.com/read/28925327/treatment-of-chronic-hepatitis-c-virus-infection-with-crushed-ledipasvir-sofosbuvir-administered-via-a-percutaneous-endoscopic-gastrostomy-tube
#15
Lauren Jindracek, Jennifer Stark
INTRODUCTION: Ledipasvir/sofosbuvir (Harvoni®) is a fixed-dose tablet indicated for the treatment of chronic hepatitis C virus (HCV) infection. There are currently no data available on the safety and efficacy of crushed ledipasvir/sofosbuvir tablets. CASE SUMMARY: This report describes the first documented case of successful treatment of chronic HCV infection in a patient crushing ledipasvir/sofosbuvir for administration via a percutaneous endoscopic gastrostomy (PEG) tube...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28923507/pentagalloylglucose-a-highly-bioavailable-polyphenolic-compound-present-in-cortex-moutan-efficiently-blocks-hepatitis-c-virus-entry
#16
Patrick Behrendt, Paula Perin, Nicolas Menzel, Dominic Banda, Stephanie Pfaender, Marco P Alves, Volker Thiel, Phillip Meulemann, Che C Colpitts, Luis M Schang, Florian W R Vondran, Anggakusuma, Michael P Manns, Eike Steinmann, Thomas Pietschmann
Approximately 142 million people worldwide are infected with hepatitis C virus (HCV). Although potent direct acting antivirals are available, high costs limit access to treatment. Chronic hepatitis C virus infection remains a major cause of orthotopic liver transplantation. Moreover, re-infection of the graft occurs regularly. Antivirals derived from natural sources might be an alternative and cost-effective option to complement therapy regimens for global control of hepatitis C virus infection. We tested the antiviral properties of a mixture of different Chinese herbs/roots named Zhi Bai Di Huang Wan (ZBDHW) and its individual components on HCV...
September 15, 2017: Antiviral Research
https://www.readbyqxmd.com/read/28922704/direct-acting-antivirals-for-chronic-hepatitis-c
#17
REVIEW
Janus C Jakobsen, Emil Eik Nielsen, Joshua Feinberg, Kiran Kumar Katakam, Kristina Fobian, Goran Hauser, Goran Poropat, Snezana Djurisic, Karl Heinz Weiss, Milica Bjelakovic, Goran Bjelakovic, Sarah Louise Klingenberg, Jian Ping Liu, Dimitrinka Nikolova, Ronald L Koretz, Christian Gluud
BACKGROUND: Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs), e.g. sofosbuvir, are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response). Sustained virological response (SVR) is used by investigators and regulatory agencies as a surrogate outcome for morbidity and mortality, based solely on observational evidence...
September 18, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28922445/position-paper-on-treatment-of-hepatitis-c-in-romania-2017-part-two
#18
Liana Gheorghe, Ioan Sporea, Speranta Iacob, Roxana Sirli, Anca Trifan, Mircea Diculescu, Carol Stanciu, Oliviu Pascu, Monica Acalovschi, Ciprian Brisc, Cristina Cijevschi, Cristian Gheorghe, Zeno Spârchez, Ion Rogoveanu, Daniela Dobru, Dan L Dumitrascu
BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is a common condition with endemic prevalence in some areas of the world. In Romania, the mean prevalence is about 3%. New treatments have become available on the market in recent years and new drugs are in the pipeline. A re-evaluation of HCV therapy was considered mandatory. The Romanian Society of Gastroenterology and Hepatology undertook this task for the practitioners of this country. METHODOLOGY: A group of recognized experts was created who screened the available literature and the major available guidelines...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28915795/future-complications-of-chronic-hepatitis-c-in-a-low-risk-area-projections-from-the-hepatitis-c-study-in-northern-norway
#19
H Kileng, L Bernfort, T Gutteberg, O S Moen, M G Kristiansen, E J Paulssen, L K Berg, J Florholmen, R Goll
BACKGROUND: Hepatitis C (HCV) infection causes an asymptomatic chronic hepatitis in most affected individuals, which often remains undetected until cirrhosis and cirrhosis-related complications occur. Screening of high-risk subjects in Northern Norway has revealed a relatively low prevalence in the general population (0.24%). Despite this, late complications of HCV infection are increasing. Our object was to estimate the future prevalence and complications of chronic HCV infection in the period 2013-2050 in a low-risk area...
September 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28914697/are-we-ready-to-treat-hepatitis-c-virus-in-individuals-with-opioid-use-disorder-assessment-of-readiness-in-european-countries-on-the-basis-of-an-expert-generated-model
#20
Nat Wright, Jens Reimer, Lorenzo Somaini, Carlos Roncero, Icro Maremmani, Nicolas Simon, Peter Krajci, Richard Littlewood, Oscar D'Agnone, Hannu Alho, Benjamin Rolland
Individuals with a history of injecting drugs have a high prevalence of chronic hepatitis C (HCV) infection. Many have a history of opioid use disorder (OUD). Despite novel treatments with improved efficacy and tolerability, treatment is limited in the group. A faculty of experts shared insights from clinical practice to develop an HCV care-readiness model. Evidence and expert knowledge was collected. Ten experts developed a model of three factors (with measures): 'healthcare engagement', 'guidance' and 'place'...
September 13, 2017: European Journal of Gastroenterology & Hepatology
keyword
keyword
15264
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"